UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Editorial: Noninvasive tests for metabolic dysfunction‐associated steatotic liver disease: A refinement of the Nash‐FibroTest for type 2 diabetes mellitus

Alimentary pharmacology & therapeutics, 2023-11, Vol.58 (10), p.1111-1112

Liu, Chen‐Hua

2023

Volltextzugriff (PDF)

Oil spills adsorption and cleanup by polymeric materials: A review

Polymers for advanced technologies, 2022-05, Vol.33 (5), p.1353-1384

2022

Volltextzugriff (PDF)

High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load

Gastroenterology (New York, N.Y. 1943), 2012-05, Vol.142 (5), p.1140-1149.e3

2012

Volltextzugriff (PDF)

Acute hepatitis C virus infection: clinical update and remaining challenges

Clinical and molecular hepatology, 2023-07, Vol.29 (3), p.623-642

2023

Volltextzugriff (PDF)

Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals

Journal of hepatology, 2020-05, Vol.72 (5), p.839-846

2020

Volltextzugriff (PDF)

Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads

Hepatology (Baltimore, Md.), 2013-02, Vol.57 (2), p.441-450

2013

Volltextzugriff (PDF)

Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5

Hepatology international, 2022-10, Vol.16 (5), p.1001-1019

2022

Volltextzugriff (PDF)

Serum hepatitis B core‐related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load

Alimentary pharmacology & therapeutics, 2021-04, Vol.53 (8), p.908-918

2021

Volltextzugriff (PDF)

Comparison of diagnostic performance among Abbott RealTime HCV Genotyping II, Abbott HCV Genotype plus RUO, and Roche Cobas HCV Genotyping assays for hepatitis C virus genotyping

Journal of medical virology, 2024-05, Vol.96 (5), p.e29686-n/a

2024

Volltextzugriff (PDF)

Comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐acting antiviral agents in hepatitis C patients in Taiwan

Alimentary pharmacology & therapeutics, 2018-12, Vol.48 (11-12), p.1290-1300

2018

Volltextzugriff (PDF)

Letter: contraindicated drug‐drug interactions before and after initiation of direct‐acting anti‐viral agents in chronic hepatitis C patients in Taiwan. Authors’ reply

Alimentary pharmacology & therapeutics, 2019-07, Vol.50 (1), p.115-116

2019

Volltextzugriff (PDF)

HCV reinfections after viral clearance among HIV‐positive patients with recent HCV infection in Taiwan

Liver international, 2019-10, Vol.39 (10), p.1860-1867

2019

Volltextzugriff (PDF)

Editorial: nephrotoxicity and oral anti‐viral therapy for HBV‐facts or fiction?

Alimentary pharmacology & therapeutics, 2019-01, Vol.49 (2), p.229-230

2019

Volltextzugriff (PDF)

Chronic hepatitis B is associated with an increased risk of B‐cell non‐Hodgkin's lymphoma and multiple myeloma

Alimentary pharmacology & therapeutics, 2019-03, Vol.49 (5), p.589-598

2019

Volltextzugriff (PDF)

Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism

Movement disorders, 2019-12, Vol.34 (12), p.1882-1890

2019

Volltextzugriff (PDF)

Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment

Alimentary pharmacology & therapeutics, 2022-02, Vol.55 (4), p.434-445

2022

Volltextzugriff (PDF)

Editorial: comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐acting anti‐viral agents in chronic hepatitis C – authors’ reply

Alimentary pharmacology & therapeutics, 2019-01, Vol.49 (1), p.117-118

2019

Volltextzugriff (PDF)

Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real‐world effectiveness and safety in Taiwan

Liver international, 2020-04, Vol.40 (4), p.758-768

2020

Volltextzugriff (PDF)

Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase

The American journal of gastroenterology, 2022-05, Vol.117 (5), p.748-757

2022

Volltextzugriff (PDF)

Toward the hepatitis C virus elimination in Asia: The policy forum from the 2023 Asian Pacific Association of the Study of the Liver (APASL)

Journal of the Formosan Medical Association, 2023-12, Vol.122 (12), p.1234-1237

2023

Volltextzugriff (PDF)

Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment

Journal of viral hepatitis, 2020-06, Vol.27 (6), p.568-575

2020

Volltextzugriff (PDF)

Four weeks of off‐treatment follow‐up is sufficient to determine virologic responses at off‐treatment week 12 in patients with hepatitis C virus infection receiving fixed‐dose pangenotypic direct‐acting antivirals

Journal of medical virology, 2024-05, Vol.96 (5), p.e29675-n/a

2024

Volltextzugriff (PDF)

Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan

Journal of gastroenterology and hepatology, 2018-03, Vol.33 (3), p.710-717

2018

Volltextzugriff (PDF)

Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus‐coinfected patients receiving sofosbuvir‐based direct‐acting antivirals and antiretroviral therapy

Journal of viral hepatitis, 2021-06, Vol.28 (6), p.887-896

2021

Volltextzugriff (PDF)

2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations

Journal of the Formosan Medical Association, 2020-07, Vol.119 (7), p.1135-1157

2020

Volltextzugriff (PDF)

1 – 25 von 5.737

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.616)
Mit Volltextzugriff
(4.936)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(3.862)
Life Sciences & Biomedicine
(2.074)
Humans
(1.395)
Technology
(1.087)
Physical Sciences
(1.016)
Male
(891)
Female
(839)
Engineering
(611)
Chemistry
(581)
Middle Aged
(558)
Adult
(550)
Animals
(538)
Materials Science
(455)
Materials Science, Multidisciplinary
(331)
Science & Technology - Other Topics
(325)
Aged
(318)
Physics
(293)
Oncology
(264)
Mice
(262)
Engineering, Electrical & Electronic
(232)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Editorial: Noninvasive tests for metabolic dysfunction‐associated steatotic liver disease: A refinement of the Nash‐FibroTest for type 2 diabetes mellitus

Oil spills adsorption and cleanup by polymeric materials: A review

High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load

Acute hepatitis C virus infection: clinical update and remaining challenges

Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals

Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads

Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5

Serum hepatitis B core‐related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load

Comparison of diagnostic performance among Abbott RealTime HCV Genotyping II, Abbott HCV Genotype plus RUO, and Roche Cobas HCV Genotyping assays for hepatitis C virus genotyping

Comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐acting antiviral agents in hepatitis C patients in Taiwan

Letter: contraindicated drug‐drug interactions before and after initiation of direct‐acting anti‐viral agents in chronic hepatitis C patients in Taiwan. Authors’ reply

HCV reinfections after viral clearance among HIV‐positive patients with recent HCV infection in Taiwan

Editorial: nephrotoxicity and oral anti‐viral therapy for HBV‐facts or fiction?

Chronic hepatitis B is associated with an increased risk of B‐cell non‐Hodgkin's lymphoma and multiple myeloma

Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism

Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment

Editorial: comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐acting anti‐viral agents in chronic hepatitis C – authors’ reply

Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real‐world effectiveness and safety in Taiwan

Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase

Toward the hepatitis C virus elimination in Asia: The policy forum from the 2023 Asian Pacific Association of the Study of the Liver (APASL)

Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment

Four weeks of off‐treatment follow‐up is sufficient to determine virologic responses at off‐treatment week 12 in patients with hepatitis C virus infection receiving fixed‐dose pangenotypic direct‐acting antivirals

Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan

Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus‐coinfected patients receiving sofosbuvir‐based direct‐acting antivirals and antiretroviral therapy

2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations

Suchergebnisse filtern